Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine explores the current treatment landscape of idiopathic hypersomnia and the associated challenges with approving new ...
Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine, discusses promising pharmacological treatments for patients with idiopathic hypersomnia. Despite the condition of ...
Illuminate Hypersomnia Initiative Shines Light on What It's Like to Live with Idiopathic Hypersomnia
Global Community Unites to Illuminate the Challenges and Treatment Aspirations of People Living with Idiopathic Hypersomnia WEST PALM BEACH, Fla., Dec. 7, 2023 /PRNewswire/ -- The Sleep Consortium, in ...
Avadel Pharmaceuticals announced that its drug LUMRYZTM received Orphan Drug Designation from the FDA for treating Idiopathic Hypersomnia (IH), a rare sleep disorder. This designation, based on the ...
WEST PALM BEACH, Fla., Sept. 17, 2024 /PRNewswire/ -- The Sleep Consortium, in partnership with a coalition of global sleep-related patient advocacy organizations, proudly announces publication of the ...
Avadel Pharmaceuticals has announced that the U.S. Court of Appeals for the Federal Circuit has ruled in its favor, allowing the company to seek FDA approval for its medication LUMRYZ to treat ...
CELEBRATION, Fla., Jan. 18, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central ...
When you feel too sleepy to see friends and loved ones, here are some tips to help you avoid loneliness. Idiopathic hypersomnia (IH) is a sleep disorder that affects how your brain controls sleep and ...
FDA grants Orphan Drug Designation (ODD) to Tris Pharma’s TRN-257 for the treatment of idiopathic hypersomnia, based on the plausible hypothesis that TRN-257 may be clinically superior to currently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results